219 related articles for article (PubMed ID: 32086326)
1. Case of paradoxical adverse response to mepolizumab with mepolizumab-induced alopecia in severe eosinophilic asthma.
Nixon R; Despiney R; Pfeffer P
BMJ Case Rep; 2020 Feb; 13(2):. PubMed ID: 32086326
[TBL] [Abstract][Full Text] [Related]
2. Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety.
van Toor JJ; van der Mark SC; Kappen JH; In 't Veen JCCM; Braunstahl GJ
J Asthma; 2021 May; 58(5):651-658. PubMed ID: 31999203
[No Abstract] [Full Text] [Related]
3. Mepolizumab (Nucala) for severe eosinophilic asthma.
Med Lett Drugs Ther; 2016 Jan; 58(1486):11-2. PubMed ID: 26761344
[No Abstract] [Full Text] [Related]
4. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
[TBL] [Abstract][Full Text] [Related]
5. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
[TBL] [Abstract][Full Text] [Related]
6. Benralizumab (Fasenra) for severe eosinophilic asthma.
Med Lett Drugs Ther; 2018 Feb; 60(1541):33-35. PubMed ID: 29485975
[No Abstract] [Full Text] [Related]
7. Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis.
Kallieri M; Zervas E; Katsoulis K; Fouka E; Porpodis K; Samitas K; Papaioannou AI; Kipourou M; Gaki E; Vittorakis S; Markatos M; Dimakou K; Ampelioti S; Koukidou S; Makris M; Ntakoula M; Mitrova MH; Glynos K; Antoniou KM; Gaga M; Tzanakis N; Markopoulou K; Papakosta D; Bakakos P; Loukides S
Int Arch Allergy Immunol; 2020; 181(8):613-617. PubMed ID: 32570256
[TBL] [Abstract][Full Text] [Related]
8. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
[TBL] [Abstract][Full Text] [Related]
9. Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma.
Comberiati P; McCormack K; Malka-Rais J; Spahn JD
J Allergy Clin Immunol Pract; 2019; 7(8):2689-2696.e2. PubMed ID: 31201938
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma.
Pertzov B; Unterman A; Shtraichman O; Shitenberg D; Rosengarten D; Kramer MR
J Asthma; 2021 Jan; 58(1):79-84. PubMed ID: 31479312
[TBL] [Abstract][Full Text] [Related]
11. Mepolizumab for Treatment of Severe Eosinophilic Asthma: A 5-Year Real-World Experience.
Loli-Ausejo D; Perdomo G; Mascaró B; Martínez-Olondris P; Sánchez-Fernández MC; Mullol J; Valero A; Arismendi E; Bobolea I
J Investig Allergol Clin Immunol; 2023 Jun; 33(3):209-210. PubMed ID: 36820628
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma.
Shimoda T; Odajima H; Okamasa A; Kawase M; Komatsubara M; Mayer B; Yancey S; Ortega H
Allergol Int; 2017 Jul; 66(3):445-451. PubMed ID: 28110896
[TBL] [Abstract][Full Text] [Related]
13. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study.
Lugogo N; Domingo C; Chanez P; Leigh R; Gilson MJ; Price RG; Yancey SW; Ortega HG
Clin Ther; 2016 Sep; 38(9):2058-2070.e1. PubMed ID: 27553751
[TBL] [Abstract][Full Text] [Related]
14. Severe uncontrolled eosinophilic asthma, which responded to benralizumab after failure to respond to mepolizumab.
Kurosawa M; Sutoh E
Ann Allergy Asthma Immunol; 2019 Apr; 122(4):431-433. PubMed ID: 30578859
[No Abstract] [Full Text] [Related]
15. Pharmacokinetic drug evaluation of mepolizumab for the treatment of severe asthma associated with persistent eosinophilic inflammation in adults.
Kallur L; Gonzalez-Estrada A; Eidelman F; Dimov V
Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1275-1280. PubMed ID: 29157020
[TBL] [Abstract][Full Text] [Related]
16. Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy.
Howarth P; Chupp G; Nelsen LM; Bradford ES; Bratton DJ; Smith SG; Albers FC; Brusselle G; Bachert C
J Allergy Clin Immunol; 2020 Jun; 145(6):1713-1715. PubMed ID: 32084443
[No Abstract] [Full Text] [Related]
17. Secondary loss of response to mepolizumab in severe eosinophilic asthma.
Cormier M; Chaboillez S; Lemiere C
J Allergy Clin Immunol Pract; 2020 Feb; 8(2):736-738. PubMed ID: 31421278
[No Abstract] [Full Text] [Related]
18. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
[TBL] [Abstract][Full Text] [Related]
19. A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting.
Cameli P; Bergantini L; d'Alessandro M; Perruzza M; Cekorja B; Perillo F; Massa E; Ruzza A; Fossi A; Beltrami V; Sestini P; Bargagli E
Int Arch Allergy Immunol; 2020; 181(8):606-612. PubMed ID: 32516771
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma.
Yancey SW; Ortega HG; Keene ON; Mayer B; Gunsoy NB; Brightling CE; Bleecker ER; Haldar P; Pavord ID
J Allergy Clin Immunol; 2017 Apr; 139(4):1167-1175.e2. PubMed ID: 27726946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
